Acquisition - August 20, 2024
Labquality acquires Scandinavian CRO
The acquisition aligns with Labquality’s international growth strategy and enables Labquality to grow its business in Sweden and to enter new markets like Norway and Denmark, it states. “Scandinavian CRO is a great addition to our Labquality family completing our CRO business platform. Now, we are a full service CRO company, and we can continue […]
Acquisition - September 27, 2023
Scantox acquires Q&Q Labs
With this acquisition Scantox has nearly 200 employees across four sites. “Scantox embarked on an ambitious growth journey when we acquired the first two international companies last year, and we are thrilled to now expand our Group further with the acquisition of Q&Q. We welcome a company known for their solid expertise within the field […]
Acquisition - March 27, 2023
Pharm Assist is now part of LINK Medical
LINK Medical has announced the integration of Pharm Assist into the LINK Medical family. “We are very excited to have Pharm Assist integrate with our network of expert teams, especially strengthening our already robust regulatory group making us very unique in our industry. Our Regulatory team across the Nordics now has over 60 specialists, including […]
CRO - November 21, 2022
LINK Medical appoints new CEO
The Board of LINK Medical has announced the appointment of Sissel Lønning Andresen as the company’s new CEO. Ola Gudmundsen will remain in the company in a strategic role where he will work closely with Lønning Andresen, and support the Business Development and Commercial Operations team. He will remain an important owner of the company […]
CRO - May 2, 2022
Serendipity has been invited as a part owner of LINK Medical
Serendipity Partners (Serendipity) now owns 49% of the shares, however, Dr. Ola Gudmundsen will still hold the majority of the shares. The transaction is mainly structured as a share issue, where Serendipity provides growth capital to LINK Medical, states the company. Co-owners and long-term investors To enable further growth and provide new competencies to the […]
Agreement - January 25, 2018
Alligator contracts Theradex Oncology as clinical CRO
Alligator Biosciencehas appointed Theradex Oncology as CRO for their planned phase I study of ATOR-1015 for the treatment of metastatic cancer. The upcoming clinical phase I study with ATOR-1015 is a first-in-human dose escalation study in patients with metastatic cancer. The study will be conducted at five sites in Sweden and Denmark. “Engaging Theradex is a key step […]
